Topics

Novartis Announces Positive Results from Phase III PALLADIUM Study of Inhaled Combination QMF149 in Patients with Uncontrolled Asthma

23:10 EDT 29 Sep 2019 | Drugs.com

Basel, September 30, 2019 – Novartis today announced that investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate or IND/MF) was superior to mometasone furoate (MF) in improving trough forced...

Original Article: Novartis Announces Positive Results from Phase III PALLADIUM Study of Inhaled Combination QMF149 in Patients with Uncontrolled Asthma

NEXT ARTICLE

More From BioPortfolio on "Novartis Announces Positive Results from Phase III PALLADIUM Study of Inhaled Combination QMF149 in Patients with Uncontrolled Asthma"

Quick Search

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...